Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2017 February;152(1) > Giornale Italiano di Dermatologia e Venereologia 2017 February;152(1):13-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Giornale Italiano di Dermatologia e Venereologia 2017 February;152(1):13-7

DOI: 10.23736/S0392-0488.16.05201-9

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Efficacy and safety of a 12-month treatment with a combination of hydroxypinacolone retinoate and retinol glycospheres as maintenance therapy in acne patients after oral isotretinoin

Vincenzo BETTOLI, Stefania ZAULI, Alessandro BORGHI, Giulia TONI, Michela RICCI, Alberto M. BERTOLDI, Annarosa VIRGILI

Section of Dermatology, Department of Medical Sciences, University of Ferrara, Sant’Anna Hospital, Ferrara, Italy


PDF


BACKGROUND: A correct therapeutic management of acne should include a maintenance therapy to prevent recurrences after discontinuing a successful treatment. The aim of this study is to investigate efficacy and safety of a 12-month maintenance treatment with a product, based on Retinsphere technology that combines retinol encapsulated in glycospheres and hydroxypinacolone retinoate (Biretix gel®), to control acne relapse after a treatment with oral isotretinoin (O.I.).
METHODS: The study consisted of 2 phases: active treatment phase (AP) and maintenance phase (MP). In the AP, 40 consecutive patients with moderate facial acne were treated with O.I. until acne remission. Then, the patients entered in the MP and were treated with Biretix gel® once-daily for 12 months. The efficacy parameter was the relapse rate during MP.
RESULTS: Thirty-nine patients completed the study. Relapse appeared in 6 patients (15.38%). The new product with Retinsphere technology was well tolerated and none of the subjects complained of adverse events.
CONCLUSIONS: Our findings seems to provide favorable evidence of the efficacy and the safety of this new product in the maintenance treatment after O.I. in patient with moderate acne. The efficacy is maintain for a period as long as a year after O.I. suspension.


KEY WORDS: Acne vulgaris - Retinoids - Isotretinoin

top of page